Investors
| Date | Resolution |
|---|---|
| 2024.11.07 | The case of the disposition of shares in "Transformative Cell Processing Co., Ltd." |
| 2024.10.09 | • Revision of the company's "Board of Directors, Functional Committees, and Executive Compensation Guidelines" • Formulation of the company's "Cash Capital Increase Employee Stock Subscription Guidelines |
| 2024.09.02 | The company is conducting a cash capital increase to issue new shares. |
| 2024.08.12 | • Q2 2024 Financial Report • Formulation of the "Financial and Business-related Operational Guidelines for Interrelated Parties," "Standard Operating Procedures for Handling Requests from Directors," "Management of Board Meeting Operations," and "Management of Audit Committee Meeting Operations" • Appointment of the Company's Corporate Governance Officer |
| 2024.06.27 | • Appointment of the company's Chief Executive Officer (CEO) • Lifting of the non-compete restrictions on the CEO • Remuneration for the members of the 2nd Audit Committee |
| 2024.06.19 | • Election of the Chairman of the Board • Appointment of the members of the 3rd Compensation and Remuneration Committee |
| 2024.05.14 | • Appointment of medical institutions for the Phase II clinical trial of TregCel™ (TRK-001), a cell therapy product of the U.S. subsidiary • Appointment of medical institutions for the Phase I clinical trial of MSC/VEGF product • Investment in Hyperius Biotech Inc. • Lifting of non-compete restrictions on executives • Obtaining a financing line from Taiwan Cooperative Bank (TCB). |
| 2024.05.09 | Board of Directors' Nomination and Changes to the List of Director Candidates |
| 2024.03.28 | • Approval of the non-assurance services to be provided by Ernst & Young and its affiliates • 2023 Annual Business Report and Financial Statements • 2023 Loss Compensation Plan • Company's Proposal to Apply for Stock Listing (or OTC) • Issuance of new shares through a public offering of cash capital increase prior to initial listing (or OTC), with all original shareholders waiving their subscription rights • Execution of a private placement of common stock for a cash capital increase in 2024 • Revision of the "Articles of Incorporation" • Complete Re-election of Directors • Nomination List of Director Candidates • Lifting of non-compete restrictions on newly appointed directors and their representatives • 2024 Annual Shareholders' Meeting Convening • 2023 Internal Control System Effectiveness Assessment and Internal Control System Declaration • The company's capital increase in its U.S. subsidiary, PhiBio Therapeutics Inc. • Appointment of medical institutions for the clinical trial of the subsidiary's product TregCel™ (TRK-001) |
| 2024.01.31 | The company’s purchase of production equipment. |